Ten stocks soared higher on Wednesday, mirroring a robust broader market performance, as investors took heart from a flurry of company-specific developments.
On Wall Street, all three major indices finished in the green, led by the Nasdaq, up 1.54 percent, followed by the Dow Jones, jumping 1.31 percent, and the S&P 500, rising 1.08 percent.
Indices aside, this article focuses on the 10 top-performing names on Wednesday and breaks down the reasons behind their gains.
To come up with the list, we considered the stocks with a $2 billion market capitalization and 5 million shares in trading volume.
Photo by Mizuno K on Pexels
10. POET Technologies Inc. (NASDAQ:POET)
POET Technologies snapped a three-day losing streak on Wednesday, climbing 13.08 percent to close at $14.78 apiece, after announcing an aggressive plan to expand its wafer manufacturing capabilities by 10x by 2027.
In an updated report, POET Technologies Inc. (NASDAQ:POET) said that it is currently in the process of expanding capacity “by roughly tenfold” in both wafer production and optical engine assembly.
“This expansion is being driven by the agreement we announced last week with Lumilens as well as other high-volume opportunities that are near fruition. In parallel with our manufacturing scale-up, we have accelerated the hiring of engineering, technical, and management talent, bringing our total headcount to more than 115 globally. We have also expanded our Singapore lab and office footprint by nearly three times compared to last year and now have 20,000 square feet of assembly space in Malaysia,” POET Technologies Inc. Chairman and CEO Suresh Venkatesan.
The company recently bagged a new supply deal with Lumilens Inc. with the potential to generate $500 million in revenues over the next five years.
It is also setting its sights on acquiring and partnering with companies that could help strengthen its engineering capabilities, broaden its product portfolio, and enhance strategic technologies and components.
In line with the expansion plan, POET Technologies Inc. earlier this week successfully raised $400 million in fresh funds from the sale of over 19 million common shares and warrants exercisable for the same size, to a single institutional investor. The shares were priced at $21 apiece, while the warrants are exercisable at $26.25 each, or a 25 percent premium over the selling price of the shares.
9. USA Rare Earth Inc. (NASDAQ:USAR)
USA Rare Earth rebounded on Wednesday, soaring 13.05 percent to finish at $22.57 apiece, as investors resorted to bargain-hunting while repositioning portfolios amid uncertainties over a rare earth deal between the US and China.
The rally was a bounce from seven straight days of volatility and losses that easily slashed the company’s share price by 25 percent, supported by the lack of concrete developments on rare earths between the US and China.
Last week, President Donald Trump met with his Chinese counterpart, Xi Jinping, to discuss key areas to resolve and work on, but developments on rare earths made little progress.
For USA Rare Earth Inc. (NASDAQ:USAR), easing of Chinese restrictions and any potential resolution between the two countries will generally be detrimental to growth, since the company has been largely benefiting from Washington’s push to secure a domestic supply chain for rare earths and critical minerals.
If tensions ease and Chinese supply becomes more accessible to the global market, concerns could emerge over reduced urgency for domestic sourcing.
In other news, USA Rare Earth Inc. last month successfully acquired rare earth miner Serra Verde Group for $2.8 billion.
Serra Verde owns the Pela Ema rare earth mine and processing plant in Goiás, Brazil, and will be acquired for a combination of $300 million cash and more than 126.8 million USAR shares.
The transaction is expected to close in the third quarter of the year, subject to customary closing conditions and regulatory approvals.
8. Enphase Energy Inc. (NASDAQ:ENPH)
Enphase Energy rebounded by 13.67 percent on Wednesday to close at $53.15 apiece, as investors cheered Goldman Sachs’ reaffirmation of a bullish stance for its stock and raising of its price target by double-digits.
In a market note, Goldman Sachs upgraded its price target for Enphase Energy Inc. (NASDAQ:ENPH) by 11.8 percent to $57 from $51 previously, while maintaining a “buy” recommendation. The price marked a 7.2 percent upside potential from its latest closing price.
The positive coverage came amid the looming July 4 deadline for a federal solar tax credit, under which, projects must begin construction and equipment must be safely harbored by the deadline for developers to qualify for a 30-percent incentive. This is expected to boost sales of solar and technology companies on the expectation that customers would scramble to place their orders prior to the deadline to qualify for the incentive.
In other news, Enphase Energy Inc. on Monday unveiled a new PowerMatch technology for two IQ Battery systems—a 5P and a 10c—which intelligently adjust IQ battery operations to match a home’s real-time power needs.
The 10C variant is available for sale in the US and Puerto Rico, while the 5P is now for sale across North America and select countries in Central America and the Caribbean.
Enphase Energy Inc. said that the two products would help deliver more usable energy, improved efficiency, and long-term savings for its customers.
7. Roivant Sciences Ltd. (NASDAQ:ROIV)
Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors took heart from its swing to profitability in the fourth quarter of fiscal year 2026, while positioning portfolios ahead of the launch of its autoimmune disease treatment.
In an updated report, Roivant Sciences Ltd. (NASDAQ:ROIV) said that it swung to an attributable net income of $302.99 million from a $206.47 million attributable net loss in the same period last year, thanks to a $415 million operating income, which reversed a $284.96 million operating loss in the same period.
Revenues, on the other hand, fell by 66.7 percent to $2.52 million from $7.57 million in the same quarter last year.
Looking ahead, Roivant Sciences Ltd. is targeting to commercially launch by the end of September its oral treatment, brepocitinib, to treat severe and rare autoimmune conditions.
Roivant Sciences Ltd. said that the Food and Drug Administration has officially accepted its new drug application for the therapy, with an assigned target action date in the third quarter of the year.
6. Arm Holdings PLC (NASDAQ:ARM)
Arm Holdings extended its winning streak to a third straight day on Wednesday to hit a new all-time high, as investors continued to take heart from an investment firm’s highly optimistic stance for its stock, saying that profits are expected to rocket fivefold by 2030.
In intra-day trading, the stock climbed to its highest price of $259.44 before trimming gains to finish the session just up by 15.05 percent at $256.73 apiece.
In a market note, Bernstein assigned an outperform rating on shares of Arm Holdings PLC (NASDAQ:ARM), alongside a price target of $300, or an implied 16.8 percent upside potential from its latest closing price.
The coverage was based on the belief that the company stands to largely benefit from the renaissance of CPUs for agentic AI, given the rapid shift from chatbot to AI agents.
Bernstein also noted that Arm Holdings PLC is expected to capture a fourfold increase in CPU market share over the next four years to hit $137 billion.
“Arm stands out in server CPUs given its unparalleled power efficiency,” Bernstein said.
In other news, Arm Holdings PLC reported a 49 percent jump in its net income in the fourth quarter of fiscal year 2026 to $313 million from $210 million in the same period last year. Revenues also increased by 20 percent to $1.49 billion from $1.241 billion.
For the first quarter of fiscal year 2027 ending June, the company has set a revenue outlook of $1.26 billion, plus or minus $50 million. This would imply a 19.6 percent jump from the $1.053 billion reported in the same period a year earlier.
5. Astera Labs Inc. (NASDAQ:ALAB)
Astera Labs rallied for a second day on Wednesday to notch a new all-time high, as investors resumed buying positions after an investment firm assigned a bullish stance on its stock.
Earlier in the week, Evercore ISI issued an outperform rating and a $297 price target for shares of Astera Labs Inc. (NASDAQ:ALAB), boosting optimism and helping propel its actual share price to as much as $287.70 during the day—its highest on record. It trimmed a few cents toward the end of the session to finish up by 17.69 percent at $287.48 apiece.
Investors also loaded portfolios following CEO Jitendra Mohan’s participation at the JPMorgan annual Global Technology, Media and Communications Conference, where he presented Astera Labs Inc.’s newest AI data center networking solutions.
On May 27, the company would also partake in the 54th Annual Technology, Media & Telecom Conference by TD Cowen in New York, as well as the 2026 Evercore Global TMT Conference in San Francisco on June 3.
In other news, the company earlier this month unveiled a new memory-semantic fabric switch called the Scorpio X-Series 320 Lane, designed to improve token economics and support large-scale clusters with minimal latency.
According to Astera Labs Inc., Scorpio’s software-defined architecture is designed to integrate seamlessly with leading merchant and custom silicon, enabling AI labs and hyperscalers to integrate and deploy new accelerator platforms for both training and inference.
4. Navitas Semiconductor Corp. (NASDAQ:NVTS)
Navitas Semiconductor snapped a three-day losing streak on Wednesday, soaring 18.32 percent to close at $22.99 apiece as investors loaded portfolios ahead of its participation in a conference.
In a notice on its website, Navitas Semiconductor Corp. (NASDAQ:NVTS) said that it would participate in the PCIM 2026 in Nuremberg, Germany, for the entire three-day event, mainly focusing on key areas such as automotive, AI, humanoid robots, the evolution in data center power distribution, riding the SiC wave efficiently, and the future of GaN.
It will also showcase its latest gallium nitride (GaN) and GeneSiC silicon carbide (SiC) power semiconductors catered to the needs of AI data centers, energy and grid infrastructure, and industrial electrification.
Navitas Semiconductor Corp. said that it will specifically exhibit two solutions that enable a swifter transition to the 800 VDC standard using GaN, as well as two SST topologies enabled by Navitas GeneSiC UHV and HV technology.
In other news, Navitas Semiconductor Corp. more-than-doubled its net loss in the first quarter of the year to $33.78 million from $16.8 million in the same period last year. Net revenues also declined by 38 percent to $8.6 million from $14 million year-on-year.
3. Xanadu Quantum Technologies Ltd. (NASDAQ:XNDU)
Xanadu snapped a three-day losing streak on Wednesday, surging by 20.56 percent to close at $14.13 apiece, as investors resorted to bargain-hunting, supported by continued optimism for the photonics sector.
Since the start of the month, Xanadu Quantum Technologies Ltd. (NASDAQ:XNDU) has already seen its share price drop by as much as 59 percent, dragged by a 68.8 percent deeper net loss in the first quarter of the year, at $20.6 million versus $12.2 million in the same period last year.
Revenues, on the other hand, increased by 305 percent to $2.832 billion from $699 million year-on-year.
Further weighing in on investor sentiment was news last week that it would issue new shares through an at-the-market facility offering in support of plans to raise $300 million in fresh funds, proceeds of which will be used to fund the continued development of its quantum computing technology roadmap.
Xanadu Quantum Technologies Ltd. is a newly listed company that only went public on March 23 through a merger with Crane Harbor Acquisition Corp., a special purpose acquisition company. Its systems and software are used by various industries, including defense, aerospace, pharmaceuticals, semiconductors, and automotive sectors, among others.
2. T1 Energy Inc. (NYSE:TE)
T1 Energy soared by 26.45 percent on Wednesday to close at $8.70 apiece, as investors took heart from an investment firm’s strong optimism for the stock, after getting battered by a short seller, which claimed that it is not eligible for US tax credits.
In a market note, Roth Capital recommended investors take the sell-off as a buying opportunity, saying that T1 Energy Inc. (NYSE:TE) is a “model for what the Trump administration may want in a domestic manufacturer that is transferring advanced technology and capacity to the US.”
Earlier in the week, T1 Energy Inc. was hit by a short seller report by Fuzzy Panda, saying that the company was not compliant with the foreign entity of concern (FEOC) regulations, and thus not eligible for tax credits from the US government.
The report said that T1 Energy Inc.’s sale of intellectual property to Singaporean firm Evervolt was designed to achieve FEOC compliance, but that the latter had undisclosed connections with Chinese solar firm Trina Solar.
Fuzzy Panda claimed that Evervolt, owned by Tan Chin Piaw, has maintained business relationships with Trina Solar for more than 15 years, and that 99 percent of its revenues came from the latter.
1. Immunovant Inc. (NASDAQ:IMVT)
Immunovant saw its share prices soar to a new five-year high on Wednesday, as investors took heart from the stellar results of its clinical trial to study its drug candidate for hard-to-treat rheumatoid arthritis.
In an updated report, Immunovant Inc. (NASDAQ:IMVT) said that its treatment candidate, IMVT-1402, showed clinically meaningful response rates of 72.7 percent ACR20, 54.5 percent ACR50, and 35.8 percent ACR70 at Week 16.
Immunovant Inc. said that it would announce further updates on the program in the second half of 2026.
Following the results, the company’s shares climbed to their highest price of $36.28 before paring gains to end the session just up by 35.26 percent at $35.56 apiece.
In other news, investment firm Stifel reiterated its “buy” recommendation and $49 price target for Immunovant Inc., reflecting its confidence that the results would soon progress to the regulatory approval stage and commercial launch.
The biopharmaceutical company also reported its earnings performance in the first quarter of the year, with net losses widening by 38.9 percent to $147.8 million from $106.4 million in the same period last year.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
